GSK Acquires Cancer Specialist Nuvalent for $10.6 Billion
$10. 6B deal: GSK to buy US cancer specialist Nuvalent
Image: The Economic Times
British pharmaceutical company GSK has announced a $10.6 billion acquisition of Nuvalent, a Boston-based cancer treatment specialist. This move aims to enhance GSK's oncology portfolio in the U.S., including three lung cancer therapies in development.
- 01GSK's acquisition of Nuvalent is valued at $10.6 billion.
- 02The deal includes three lung cancer therapies currently in testing.
- 03Two of these therapies, zidesamtinib and neladalkib, could launch this year pending FDA approval.
- 04GSK aims to leverage its infrastructure to commercialize these drugs effectively.
- 05The U.S. market contributed over half of Nuvalent's revenue last year.
Advertisement
In-Article Ad
GSK, a British pharmaceutical group, has announced its acquisition of Nuvalent, a cancer treatment specialist based in Boston, for $10.6 billion. This strategic move enhances GSK's focus on oncology and strengthens its presence in the U.S. market. The acquisition includes three lung cancer therapies currently undergoing testing, with zidesamtinib and neladalkib identified as potential best-in-class treatments that could launch this year, pending approval from the U.S. Food and Drug Administration. GSK's CEO, Luke Miels, emphasized the company's commitment to supporting the commercialization of these therapies, while Nuvalent's CEO, James Porter, highlighted the importance of GSK's expertise in advancing their drug discovery pipeline. Notably, the U.S. accounted for more than half of Nuvalent's revenue last year.
Advertisement
In-Article Ad
GSK's acquisition could lead to new cancer treatments available in the U.S. market, potentially improving patient outcomes.
Advertisement
In-Article Ad
Reader Poll
What do you think about GSK's acquisition of Nuvalent?
Connecting to poll...
Read the original article
Visit the source for the complete story.